- Home
- IMCR vs CXM Comparison
IMCR vs CXM Comparison
Compare IMCR & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- CXM
- Stock Information
- Founded
- IMCR 2008
- CXM 2009
- Country
- IMCR United Kingdom
- CXM United States
- Employees
- IMCR N/A
- CXM N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- CXM Computer Software: Prepackaged Software
- Sector
- IMCR Health Care
- CXM Technology
- Exchange
- IMCR Nasdaq
- CXM Nasdaq
- Market Cap
- IMCR 1.8B
- CXM 2.1B
- IPO Year
- IMCR 2021
- CXM 2021
- Fundamental
- Price
- IMCR $37.20
- CXM $7.80
- Analyst Decision
- IMCR Buy
- CXM Hold
- Analyst Count
- IMCR 9
- CXM 14
- Target Price
- IMCR $57.00
- CXM $9.93
- AVG Volume (30 Days)
- IMCR 284.7K
- CXM 2.3M
- Earning Date
- IMCR 11-05-2025
- CXM 09-03-2025
- Dividend Yield
- IMCR N/A
- CXM N/A
- EPS Growth
- IMCR N/A
- CXM 163.85
- EPS
- IMCR N/A
- CXM 0.45
- Revenue
- IMCR $356,145,000.00
- CXM $820,768,000.00
- Revenue This Year
- IMCR $31.83
- CXM $4.75
- Revenue Next Year
- IMCR $8.50
- CXM $5.11
- P/E Ratio
- IMCR N/A
- CXM $17.33
- Revenue Growth
- IMCR 26.78
- CXM 6.08
- 52 Week Low
- IMCR $23.15
- CXM $6.75
- 52 Week High
- IMCR $39.33
- CXM $9.69
- Technical
- Relative Strength Index (RSI)
- IMCR 76.55
- CXM 37.98
- Support Level
- IMCR $31.85
- CXM $7.51
- Resistance Level
- IMCR $33.08
- CXM $8.85
- Average True Range (ATR)
- IMCR 1.28
- CXM 0.32
- MACD
- IMCR 0.50
- CXM -0.06
- Stochastic Oscillator
- IMCR 100.00
- CXM 21.72
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.